Renal resistive index measurements by ultrasound in patients with liver cirrhosis: Magnitude and associations with renal dysfunction

doi:10.4329/wjr.v16.i6.221

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (355)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

HTML

178

Figures (1-2)

Tables (1-4)

Sum=245

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=94

Publishing Process of This Article

Item

Count

Browse

Download

Sum=5

Jun 28, 2024 (publication date) through Jul 9, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Radiology

ISSN

1949-8470

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Radiol. Jun 28, 2024; 16(6): 221-231
Published online Jun 28, 2024. doi: 10.4329/wjr.v16.i6.221

Table 1 Baseline clinical characteristics of the study population, n = 200

Parameter	Frequency
Age in yr, mean ± SD	49.08 ± 11.68
Male, n (%)	159 (79.5)
Etiology of cirrhosis, n (%)
Alcohol	78 (39.0)
NAFLD	49 (24.5)
Viral	37 (18.5)
Others	36 (18.0)
CTP Class, n (%)
A	23 (11.5)
B	66 (33.0)
C	111 (55.5)
Cirrhosis duration in mo, median (IQR)	6.00 (2.001-4.40)
CTP score, mean ± SD	9.59 ± 2.27
MELD-Na score, median	21 (7-40) ± 7.19
BMI, mean ± SD	19.79 ± 3.05
Comorbidity, n (%)
None	121 (60.5)
Type 2 DM	34 (17.0)
HTN	44 (22.0)
Hypothyroidism	1 (0.5)
Duration of type 2 DM in mo, mean ± SD	23.94 ± 13.3
Duration of HTN in mo, mean ± SD	24.09 ± 11.84
ACLF presence, n (%)	27 (13.5)
ACLF grade among n = 27, n (%)
I	6 (22.2)
II	10 (37.0)
III	11 (40.7)
Abdominal circumference in cm, mean ± SD	95.64 ± 16.28
Ascites among n = 153, n (%)
Grade II	70 (45.7)
Grade III	83 (54.3)
Diuretic responsive	90 (59.0)
Diuretic resistant	63 (41.0)
MAP in mmHg, mean ± SD	76.16 ± 5.39
Heart rate in bpm, median (IQR)	80.00 (60.00-130.00)

ACLF: Acute-on-chronic liver failure; CTP: Child Turcotte Pugh; DM: Diabetes mellitus; HTN: Hypertension; IQR: Interquartile range; MAP: Mean arterial pressure; MELD: Model for end-stage liver disease; NAFLD: Non-alcoholic fatty liver disease; SD: Standard deviation.

Table 2 Baseline clinical characteristics according to the type of acute kidney injury, n = 200

Parameter	PRA, n = 29	ATN-AKI, n = 18	HRS-AKI, n = 82	No-AKI, n = 71	^aP value
Age in yr, mean ± SD	53.9 ± 10.1	43.3 ± 10.8	50.7 ± 11.3	46.8 ± 12.0	0.003
Sex as male/female	26/3	16/2	64/18	53/18	0.268
Etiology of cirrhosis: Alcohol/NAFLD/viral/others	15/9/4/1	14/1/2/1	25/21/25/11	24/18/17/12	0.012
Hepatic encephalopathy, n (%)	4 (13.7)	1 (5.5)	5 (6.1)	7 (9.8)	0.568
GI bleed, n (%)	1 (3.4)	0 (0.0)	2 (2.4)	55 (69.6)	< 0.001
Sepsis, n (%)	2 (6.9)	12 (66.6)	49 (59.7)	0 (0.0)	< 0.001
Shock, n (%)	0 (0.0)	18 (100.0)	0 (0.0)	0 (0.0)	< 0.001
ACLF, n (%)	0 (0.0)	13 (72.2)	14 (17.0)	0 (0.0)	< 0.001
CTP score, mean ± SD	9.83 ± 1.61	11.89 ± 1.08	10.44 ± 1.87	7.93 ± 2.08	< 0.001
MELD-Na score, mean ± SD	21.50 ± 5.54	29.60 ± 7.19	22.10 ± 7.10	17.70 ± 5.70	< 0.001
Stage of AKI: Stage 1/stage 2/stage 3	16/13/0	3/5/10	32/29/21	0/0/0	< 0.001
Ascites: No/diuretic responsive/refractory	1/26/2	0/7/11	0/34/48	46/23/2	< 0.001
Hemoglobin in g/dL, mean ± SD	7.78 ± 1.58	8.79 ± 2.27	8.87 ± 1.75	7.97 ± 2.54	0.010
Total leukocyte count as cells/mm³, mean ± SD	7410 ± 5750	13760 ± 6760	7290 ± 3990	5640 ± 3290	< 0.001
Platelet count as cells/mm³, mean ± SD	89700 ± 31600	97100 ± 27600	98000 ± 32700	98200 ± 38400	0.654
Bilirubin in mg/dL, mean ± SD	1.76 ± 1.13	10.11 ± 8.70	3.62 ± 3.35	2.20 ± 1.82	< 0.001
ALT in U/L, mean ± SD	40.5 ± 23.1	53.1 ± 24.6	57.1 ± 77.9	38.6 ± 28.9	0.078
AST in U/L, mean ± SD	64.3 ± 41.2	130.7 ± 59.1	109.4 ± 63.2	68.4 ± 66.9	< 0.001
INR, mean ± SD	1.64 ± 0.42	2.43 ± 0.66	1.83 ± 0.57	1.57 ± 0.45	< 0.001
Albumin, mean ± SD	2.80 ± 0.41	2.48 ± 0.34	2.62 ± 0.43	2.98 ± 0.47	< 0.001
Urea in mg/dL, mean ± SD	90.10 ± 20.24	33.40 ± 6.85	44.3 ± 29.68	44.0 ± 26.31	< 0.001
Creatinine in mg/dL on Day 1, mean ± SD	1.68 ± 0.191	0.911 ± 0.264	1.335 ± 0.778	0.940 ± 0.276	< 0.001
Creatinine in mg/dL on Day 3, mean ± SD	1.53 ± 0.315	3.10 ± 1.165	2.81 ± 1.537	0.975 ± 0.212	< 0.001
CRP in mg/L, mean ± SD	38.6 ± 28.1	42.2 ± 25.7	37.7 ± 32.7	23.4 ± 19.9	< 0.001
Serum sodium in mEq/L, mean ± SD	126 ± 23.52	128 ± 6.26	130 ± 6.66	133 ± 4.89	0.001
Serum potassium in mEq/L, mean ± SD	4.42 ± 0.611	4.35 ± 0.604	4.25 ± 0.668	4.14 ± 0.552	0.155
RRI, mean ± SD	0.63 ± 0.07	0.80 ± 0.02	0.73 ± 0.0	0.60 ± 0.07	< 0.001

^aP value: P < 0.05 was considered statistically significant between the groups. ACLF: Acute on chronic liver failure; AKI: Acute kidney injury; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ATN: Acute tubular necrosis; CRP: C-reactive protein; CTP: Child Turcotte Pugh; GI: Gastrointestinal; HRS: Hepatorenal syndrome; INR: International normalized ratio; MELD-Na: Model for end-stage liver disease-sodium; NAFLD: Non-alcoholic fatty liver disease; PRA: Prerenal AKI; RRI: Renal resistive index; SD: Standard deviation.

Table 3 Comparison of clinical parameters in patients with and without high RRI, n = 200

Parameters	High RRI, > 0.73, n = 82	Low RRI, ≤ 0.73, n = 118	^aP value
Age in yr, mean ± SD	47.98 ± 11.01	50.40 ± 12.37	0.810
Sex
Male, n (%)	69 (84.1)	90 (76.2)	0.170
Comorbidity, n (%)
Present	19 (23.2)	60 (50.8)	0.110
ACLF among n = 27	20 (24.3)	7 (5.9)	< 0.001
ACLF grade, n (%)
Grade I	5 (25)	1 (0.8)	0.002
Grade II	7 (35)	3 (2.5)
Grade III	8 (40)	3 (2.5)
AKI, n (%)	79 (96.3)	50 (42.4)	< 0.001
AKI stage among n = 129, n (%)
Stage I	27 (32.9)	24 (20.3)
Stage II	28 (34.1)	19 (16.1)
Stage III	24 (29.2)	7.0 (5.9)
AKI phenotype among n = 129, n (%)
ATN-AKI	17 (94.4)	1 (0.8)	< 0.001
HRS-AKI	59 (72)	23 (19.4)
PRA	3 (10.3)	26 (22.0)
BMI in kg/m²	19.70 ± 3.06	19.87 ± 3.06	0.169
Abdominal circumference in cm	102.98 ± 10.2	90.54 ± 17.6	< 0.001
Duration of cirrhosis in mo	10.96 ± 11.5	10.55 ± 12.18	0.574
Etiology, n (%)
Alcohol	31 (37.8)	47 (39.8)	0.907
NAFLD	19 (23.2)	30 (25.4)
Viral	22 (26.8)	15 (12.7)
Others	10 (12.2)	26 (22.1)
CTP class, n (%)
A	1 (1.2)	22 (18.6)	< 0.001
B	17 (20.7)	49 (41.5)
C	64 (78.1)	47 (39.8)
MELD-Na Score	23 (7-33)	19 (7-28)	< 0.001
Ascites among n = 153, n (%)
Grade-II	26 (32.5)	44 (37.2.3)	< 0.001
Grade-III	54 (67.5)	29 (24.5)	< 0.001
MAP in mmHg	73.50 ± 6.77	78.2 ± 2.61	< 0.001
Heart rate	90.8 ± 16.55	80.8 ± 7.35	< 0.001

^aP value: P < 0.05 was considered statistically significant between the groups. ACLF: Acute on chronic liver failure; AKI: Acute kidney injury; ATN: Acute tubular necrosis; BMI: Body mass index; CTP: Child Turcotte Pugh; HRS: Hepatorenal syndrome; MAP: Mean arterial pressure; MELD-Na: Model for end-stage liver disease-sodium; NAFLD: Non-alcoholic fatty liver disease; PRA: Prerenal AKI; RRI: Renal resistive index; SD: Standard deviation.

Table 4 Discriminatory performance of renal resistive index for different phenotypes of acute kidney injury

Parameters	AUROC curve	RRI cut-off	Sensitivity	Specificity	PPV	NPV
ATN-AKI vs non-ATN AKI	94%	0.77	89%	96%	80%	98%
ATN-AKI vs HRS-AKI	94%	0.77	89%	98%	94%	97%
ATN-AKI vs PRA	93%	0.73	100%	89%	85%	100%
HRS-AKI vs non HRS-AKI	56%	0.72	94%	55%	78%	84%
HRS-AKI vs PRA	87%	0.71	95%	89%	96%	86%
PRA vs no-AKI	59%	0.59	76%	45%	36%	81%

AKI: Acute kidney injury; ATN: Acute tubular necrosis; AUROC: Area under receiver operating characteristic curve; HRS: Hepatorenal syndrome; NPV: Negative predictive value; PPV: Positive predictive value; PRA: Prerenal AKI; RRI: Renal resistive index.

Citation: Surya H, Kumar R, Priyadarshi RN, Surya Prakash S, Kumar S. Renal resistive index measurements by ultrasound in patients with liver cirrhosis: Magnitude and associations with renal dysfunction. World J Radiol 2024; 16(6): 221-231
URL: https://www.wjgnet.com/1949-8470/full/v16/i6/221.htm
DOI: https://dx.doi.org/10.4329/wjr.v16.i6.221